APA (7th ed.) Citation

ML, S., G, C., CS, H., CC, D., C, R., HG, R., . . . KM, W. (2026). Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment. Transplantation and cellular therapy, 32(7), 887.e1-887.e16. https://doi.org/10.1016/j.jtct.2026.04.026

Chicago Style (17th ed.) Citation

ML, Schoettler, et al. "Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment." Transplantation and Cellular Therapy 32, no. 7 (2026): 887.e1-887.e16. https://doi.org/10.1016/j.jtct.2026.04.026.

MLA (9th ed.) Citation

ML, Schoettler, et al. "Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment." Transplantation and Cellular Therapy, vol. 32, no. 7, 2026, pp. 887.e1-887.e16, https://doi.org/10.1016/j.jtct.2026.04.026.